Seattle Seahawks running back Kenneth Walker III was named the Most Valuable Player after leading his team to a decisive 29-13 victory over the New England Patriots in Super Bowl LX on Sunday, February 8, 2026, in Santa Clara, California. Walker rushed for 135 yards on 27 carries, according to reports from ESPN and The New York Times.
The Seahawks controlled the game from the outset, a performance that contrasted with the Patriots’ struggles. New England, playing in its NFL-record 12th Super Bowl, now holds the most Super Bowl losses with six, falling to 6-6 all-time in the championship game, according to The New York Times. This defeat marked the Patriots’ third Super Bowl loss without Tom Brady and Bill Belichick at the helm.
Seattle quarterback Sam Darnold completed a 23-yard pass to Cooper Kupp early in the first drive, and later connected with tight end AJ Barner for a 15-yard gain. Jason Myers contributed to the Seahawks’ lead with a 33-yard field goal. Defensively, Seattle proved dominant, with Derick Hall and Devon Witherspoon each recording a 10-yard sack of Patriots quarterback Drake Maye. Linebackers Drake Thomas and Ernest Jones IV combined for a tackle for loss, even as Uchenna Nwosu sealed the victory with an interception returned for a touchdown in the fourth quarter, as reported by The New York Times.
The Patriots’ offensive efforts included a 26-yard pass from Maye to Stefon Diggs and a 7-yard touchdown pass to Rhamondre Stevenson, but these were insufficient to overcome Seattle’s consistent performance. Cornerback Christian Gonzalez delivered a strong performance for New England, but the team ultimately fell short.
Despite the Seahawks’ victory, the game lacked the high-flying offensive displays often associated with the Super Bowl, with a focus on field position and defensive plays. The game also highlighted the evolving landscape of the NFL, with the Seahawks emerging as a dominant force and the Patriots facing a period of transition.
Several other biotech companies have successfully held initial public offerings (IPOs) in recent weeks, showing investors that going public is once again a viable exit strategy. Since the start of the year, five biotech companies have held IPOs: radiopharmaceutical maker Aktis Oncology; alopecia drug developer Veradermics; cancer and neuroscience firm—Eikon Therapeutics; eye disease–focused SpyGlass Pharma; and minor-molecule and antibody developer Agomab Therapeutics.
FMC has retained financial and legal advisers to conduct a strategic review that may lead to the sale of the entire company. The crop protection chemical maker had a difficult 2025, with sales down 8% and a loss of $2.24 billion. Sony and 13 chemical and materials companies are organizing a biobased supply chain to provide renewable polymers for use in Sony’s electronic devices. Daicel is delaying the opening of the Topas cycloolefin copolymer plant it is building in Leuna, Germany, citing slower-than-expected demand and rising costs. Solvay has opened a new plant in Livorno, Italy, that produces highly dispersible silica from rice husk ash, an agricultural by-product. DSM-Firmenich has agreed to sell its animal health and nutrition business to CVC Capital Partners for $2.6 billion. Lhyfe has canceled plans to convert a former foundry and landfill site in western France into a plant that would make electrolytic hydrogen, due to cuts in government subsidies. Lilly to buy circular RNA developer Orna in a deal worth up to $2.4 billion. Memo Therapeutics partners with CSL in a deal worth up to $328 million.
